STREAM (Standardised Treatment Regimens of Anti-tuberculosis drugs for Multidrug-Resistant Tuberculosis) Stage 1 demonstrated non-inferior efficacy of a short regimen for rifampicin-resistant TB (RR-TB) compared to a long regimen as recommended by the World Health Organization. This study analyzed factors associated with a definite or probable failure or relapse (FoR) event in participants receiving the short regimen. The factors associated with FoR outcomes identified in this study should be considered when determining the optimal shortened treatment regimen.
Published: August 1, 2022
Sign up to receive our monthly Research Roundup email, which offers a selection of new public health research from major journals.
Recent Abstracts
Testimonials: Personal stories that have the power to save lives on the road
Knowledge, Attitudes, and Practice Study on Lead Poisoning and Pollution in Indonesia
Improving Civil Registration and Vital Statistics Systems in French-Speaking Countries: Opportunities and Challenges
Strengthening the Civil Registration and Vital Statistics (CRVS) System in Colombia
Estimation of the direct and indirect costs attributable to alcohol consumption in Brazil
Guidance for Collection and Processing of Cause-of-Death Data in the Civil Registration and…
Vital Strategies: Reimagine Public Health
Public perceptions of emissions testing in Jakarta, Indonesia
Cost-Benefit Analysis for Air Pollution Control Strategies in Jakarta
Key Messages on Alcohol Harms and Policy Solutions